This study is still in progress and includes patients using SYNTAX II score based on functional invasive evaluation with iFR / FFR and performing angioplasty guided by IVUS using the biodegradable polymer everolimus eluting stent. The study seeks to prove superiority versus the first generation paclitaxel-eluting stent and non-inferiority versus surgery using historical data. We...

This new device consists of a novolimus releasing bioabsorbable polylactic acid platform that in vitro studies has shown equivalence to a Cypher stent. This device, also in vitro , showed a degradation time of one year and safety during post expansion, reaching 4.8 mm without fracturing. This is the first human trial and follow-up with...

We included 200 patients (100 with hybrid revascularization and 100 with conventional surgery). The complete revascularization rate was similar between both groups (70%). Also, the event-free survival was similar with 92% for conventional surgery group and 89% for the hybrid. The revascularization of the anterior descending artery with breast bridge and angioplasty to the rest...

The aim of this study was to evaluate the clinical impact resistance thienopyridines through genetic analysis of CYP2C19 receptor. The primary endpoint was  a combination of mortality, myocardial infarction, stent thrombosis in the resistance group (few responders) versus non-resistant (responders) to the thienopyridines. 1445 patients were included of which 22% were considered few responders. There...

Currently the recommendation is 12 months of dual antiplatelet after a drug-eluting stent angioplasty. This study compared the 3 – months versus 12 months of dual antiplatelet  after angioplasty with zotarolimus-eluting stent in real-world patients. This was a prospective, multicenter study randomized 1563 patients to receive aspirin and clopidogrel for 3 months and 1556 to...

This study randomized 1:1,  906 patients to receive zotarolimus-eluting stent and 905 patients to receive everolimus-eluting stent. The clinical and angiographic characteristics of both groups were similar with approximately 45% of the population experiencing an acute coronary syndrome. There were no significant differences in major cardiac events between the two stents with 6.1% to for...

From the total of 1900 patients in the FREEDOM study, 1248 did not require insulin (631 received angioplasty and 617 received CABG) and 602 if required (325 received angioplasty and 277 received CABG). Insulin dependent patients were more obese, with higher glycosylated hemoglobin, increased incidence of heart failure and increased incidence of acute coronary syndromes....

Recentemente uma revisão e metanálise sobre obstrução coronária após o implante de TAVI foi publicada na revista JAAC. Este artigo foi motivo de uma aula no TCT 2013 ministrada pelo Dr. Henrique Ribeiro (autor principal deste estudo). Segue abaixo o resumo do estudo e a entrevista com o dr. Henrique: Obstrução coronária pós TAVI Fundamentos...

This study randomized 1259 patients to receive one year versus 2 years of double anti anti-platelet after implantation of a drug-eluting stent. The primary end point was a composite of death, myocardial infarction, stroke, stent thrombosis, and urgent revascularization that were equivalent between the two schemes. There was a trend to a higher rate of...

Bivalirudin reduced mortality and bleeding compared to heparin and glycoprotein IIbIIIa in HORIZONS- AMI study. However there was a higher rate of acute stent thrombosis in patients receiving bivalirudin. This randomized study (> 90 % randomized in the ambulance) enrolled 2218 patients with ASTEMIto prolonged infusion of bivalirudin compared with heparin -associated glycoprotein inhibitors. The...